Date de publication: 24 septembre 2008
Promoteur – Intermédiaire Financier
Guerbet S.A.
Lieu
Description
The project focuses on the development of new or improved contrast agents for medical imaging. If successful, they will improve the anatomic visualisation of human organs, the detection of pathologies as well as the functional evaluation of certain organs.
Objectifs
The project helps to strengthen the knowledge base and, by default, the market position of a European specialist pharmaceutical company that operates in the segmented global market for medical imaging. Furthermore, the project is expected to increase the small number of contrast agents that are currently on the market.
Secteur(s)
Montant BEI envisagé (montant approximatif)
Up to EUR 40 million.
Coût total (montant approximatif)
Estimated at around EUR 90 million.
Aspects environnementaux
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA required by EU Directive 97/11 as amended by Directive 2003/35 is therefore not required. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.
Passation des marchés
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.
Statut
Signé - 25/03/2009
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).